Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Exelixis Inc
EXEL
Healthcare
Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved...
as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:EXEL)
New Post
View:
Posts & Comments
Threaded Posts
(282)
•••
whytestocks
X
Post by
whytestocks
on Oct 30, 2024 12:45pm
Buy Recommendation Issued On EXEL By Guggenheim
BREAKING NEWS: $EXEL Buy Recommendation Issued On EXEL By Guggenheim2024-10-30 11:30:05 ET Guggenheim analyst issues BUY recommendation for EXEL on October 30, 2024 09:12AM ET. The previous analyst
...more
(282)
•••
whytestocks
X
Post by
whytestocks
on Oct 30, 2024 11:47am
EXEL Price Target Alert: $38.00. Issued by Truist Financial
Breaking News: $EXEL EXEL Price Target Alert: $38.00. Issued by Truist Financial2024-10-30 08:59:46 ET Asthika Goonewardene from Truist Financial issued a price target of $38.00 for EXEL on 2024-10-30
...more
Promino Nutritional Sciences Inc. Provides Shareholder Progress Report
posted Dec 14, 2024 9:00am by
Promino Nutritional Sciences Inc.
-
|
Promino Nutritional Science's rejuvenate muscle activator, delivers the equivalent of 40 grams of whey protein isolate for just 3.6 grams of the company’s product. That was just one of the highlights in the company’s update to investors covering a transformational period for the company as new management resurrects sales with an eye on the RTD market in 2025 ...read more
(282)
•••
whytestocks
X
Post by
whytestocks
on Oct 15, 2024 4:15pm
Exelixis to Release Third Quarter 2024 Financial Results on
News; $EXEL Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024@ Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT @ Exelixis, Inc. (Nasdaq: EXEL
...more
(282)
•••
whytestocks
X
Post by
whytestocks
on Aug 07, 2024 1:03pm
EXEL Price Target Alert: $29.00. Issued by JMP Securities
Breaking News: $EXEL EXEL Price Target Alert: $29.00. Issued by JMP Securities2024-08-07 07:00:12 ET Silvan Tuerkcan from JMP Securities issued a price target of $29.00 for EXEL on 2024-08-07 06:32:00
...more
(282)
•••
whytestocks
X
Post by
whytestocks
on May 01, 2024 8:30pm
(EXEL) Investment Report
JUST IN: $EXEL (EXEL) Investment Report2024-05-01 02:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry
...more
(2)
•••
jw1trader
X
Post by
jw1trader
on Aug 24, 2022 12:52pm
fighting cancers
with a profitable operation valued at about $7 billion and a diverse portfolio of treatments. These include its Cabometyx drug for advanced renal cell carcinoma, Cometriq for thyroid cancer and
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.